BCR-ABL T315I: the gatekeeper that broke imatinib

Imatinib was the first targeted kinase inhibitor that actually worked. It turned chronic myeloid leukemia from a death sentence into a chronic disease with near-normal life expectancy. Then a single point mutation at position 315 of ABL emerged, and four consecutive generations of inhibitors hit the same wall. The story of T315I is the cleanest illustration in oncology of why gatekeeper residues matter and what it takes structurally to get past one.

The gatekeeper, in one paragraph

Threonine 315 sits at the back of the ATP-binding pocket of ABL, directly above the hinge region. Imatinib (and dasatinib, and nilotinib, and bosutinib) all rely on a hydrogen bond between the threonine hydroxyl and the inhibitor scaffold, plus a favorable shape complementarity with the small threonine sidechain. Substitute that threonine with isoleucine and two things happen at once: you lose the hydrogen bond, and the bulkier branched isoleucine sidechain sterically clashes with the inhibitor. Both penalties stack. The drug, in practice, is gone.

The four-drug pile-up

The order matters because each generation was optimized against the resistance pattern of the previous one, and yet T315I knocked all four out:

• Imatinib (Gleevec, STI-571) — Novartis, FDA approved 2001. Type II inhibitor, binds the inactive DFG-out conformation. The original CML breakthrough. IRIS trial showed durable responses in chronic phase. T315I drops imatinib affinity by orders of magnitude.
• Dasatinib (Sprycel) — BMS, approved 2006. Type I, binds DFG-in. Also hits Src-family kinases. Effective against most imatinib-resistance mutations (Y253F, E255K, M351T) but not T315I.
• Nilotinib (Tasigna) — Novartis, approved 2007. A redesigned imatinib scaffold with better fit to the DFG-out pocket and higher absolute potency. Same gatekeeper dependency. Same failure on T315I.
• Bosutinib (Bosulif) — Pfizer, approved 2012. Dual Src/Abl inhibitor. Active against many compound mutations but, again, not T315I.

By 2010 every patient with a T315I mutation in chronic-phase CML had run out of approved options. Allogeneic stem cell transplant was the only remaining curative path, with all the morbidity that implies.

Ponatinib: the first answer

Ponatinib (Iclusig, AP24534) was designed with T315I as the explicit target. The medicinal chemistry move was a carbon-carbon triple bond linker that threads around the bulky isoleucine sidechain instead of trying to displace it. The alkyne is rigid and slim — the geometry happens to fit a pocket with either threonine or isoleucine at position 315. O'Hare et al. (2009) showed the structural basis in complex with the T315I mutant.

Clinically, the PACE trial (Cortes et al., NEJM 2013) demonstrated major cytogenetic responses in roughly 70% of T315I-positive chronic-phase patients who had failed prior TKIs. The catch was cardiovascular: arterial occlusive events emerged at concerning rates, leading to a temporary marketing suspension in 2013, a revised dose, and a black box warning that has shaped how ponatinib is dosed ever since. The OPTIC trial later validated a response-driven dose-reduction strategy that preserves efficacy while attenuating the vascular signal.

Asciminib: the allosteric end-run

Asciminib (Scemblix, ABL001) takes a different route entirely. Instead of competing with ATP, it binds the myristoyl pocket on the C-lobe of ABL — the natural docking site for the N-terminal myristoyl group that normally autoinhibits c-ABL. BCR-ABL, the fusion oncoprotein in CML, lacks that myristoyl group because the BCR fragment replaces the N-terminus. The myristoyl pocket is therefore empty and accessible in the oncogenic form. Asciminib occupies it and reimposes the autoinhibited conformation pharmacologically.

Because the binding site is nowhere near position 315, T315I has essentially no impact on asciminib affinity for that pocket. The ASCEMBL trial (Hochhaus et al., Leukemia 2023) compared asciminib head-to-head against bosutinib in heavily pretreated CML and showed superior major molecular response rates. The FDA approval for T315I-positive CML in 2021 expanded the salvage menu beyond ponatinib for the first time. Asciminib is now class STAMP (Specifically Targeting the ABL Myristoyl Pocket), and the same pocket is being explored in combination regimens with ATP-site binders to suppress emergence of compound mutations.

What this means for your docking workflow

T315I is a small experiment you can run in an afternoon and the signal is unambiguous. Imatinib will lose 2-4 kcal/mol going from wild-type ABL to T315I in any reasonable scoring function. Ponatinib should hold roughly steady because the alkyne linker accommodates either residue. Asciminib should not care at all because it is not even binding the same pocket — and a docking run that targets the ATP site for asciminib will produce nonsense scores, which is itself a useful diagnostic that you have the wrong binding-site definition.

The broader lesson is that gatekeeper mutations are the easiest WT-vs-mutant signal to recover with docking. The energetic penalty is large, the geometry change is well-localized, and the rank order across known inhibitors is well-characterized. If a workflow cannot reproduce the imatinib WT-vs-T315I gap, something is wrong with the workflow, not the biology.

Try the docking yourself

The canonical structures are 2HYY (imatinib bound to wild-type ABL), 3IK3 (ponatinib bound to the T315I mutant), and 5MO4 (asciminib in the myristoyl pocket). Open Studio and pick ABL from the target catalog with T315I from the mutation chips. Dock imatinib, ponatinib, and asciminib in turn. The WT-versus-T315I delta will tell you a clean story for the first two; for asciminib, redefine the binding site to the myristoyl pocket to see why allosteric inhibition is structurally immune to the gatekeeper.

Liganx makes molecular docking online and free: no install, no setup, just a target and a ligand in the browser. It is a quick way to see how molecular docking captures the T315I gatekeeper story across imatinib, ponatinib, and asciminib.

Primary sources

• O'Hare T, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16, 401-412 (2009). doi:10.1016/j.ccr.2009.09.028
• Cortes JE, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. NEJM 369, 1783-1796 (2013). doi:10.1056/NEJMoa1306494
• Wylie AA, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature 543, 733-737 (2017). doi:10.1038/nature21702
• Hochhaus A, et al. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia 37, 617-626 (2023). doi:10.1038/s41375-023-01829-9